PL2413956T3 - Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii - Google Patents

Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii

Info

Publication number
PL2413956T3
PL2413956T3 PL09785926T PL09785926T PL2413956T3 PL 2413956 T3 PL2413956 T3 PL 2413956T3 PL 09785926 T PL09785926 T PL 09785926T PL 09785926 T PL09785926 T PL 09785926T PL 2413956 T3 PL2413956 T3 PL 2413956T3
Authority
PL
Poland
Prior art keywords
immunotherapy
epitopes
optimization
identification
cryptic hla
Prior art date
Application number
PL09785926T
Other languages
English (en)
Polish (pl)
Inventor
Kostantinos Kosmatopoulos (Kostas)
Jeanne Menez-Jamet
Original Assignee
Vaxon Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaxon Biotech filed Critical Vaxon Biotech
Publication of PL2413956T3 publication Critical patent/PL2413956T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/975—Kit

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL09785926T 2009-04-02 2009-04-02 Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii PL2413956T3 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2009/005753 WO2010112962A1 (fr) 2009-04-02 2009-04-02 Identification, optimisation et utilisation d'épitopes hla-a24 cryptiques pour une immunothérapie

Publications (1)

Publication Number Publication Date
PL2413956T3 true PL2413956T3 (pl) 2017-06-30

Family

ID=41381983

Family Applications (1)

Application Number Title Priority Date Filing Date
PL09785926T PL2413956T3 (pl) 2009-04-02 2009-04-02 Identyfikacja, optymalizacja oraz zastosowanie kryptycznych epitopów antygenu hla-a24 na potrzeby immunoterapii

Country Status (13)

Country Link
US (1) US8900600B2 (fr)
EP (1) EP2413956B1 (fr)
JP (1) JP5756792B2 (fr)
CN (1) CN102387813B (fr)
BR (1) BRPI0924827A2 (fr)
CA (1) CA2756238A1 (fr)
DK (1) DK2413956T3 (fr)
ES (1) ES2608715T3 (fr)
HR (1) HRP20161710T1 (fr)
HU (1) HUE030195T2 (fr)
PL (1) PL2413956T3 (fr)
PT (1) PT2413956T (fr)
WO (1) WO2010112962A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102341899B1 (ko) * 2013-04-07 2021-12-21 더 브로드 인스티튜트, 인코퍼레이티드 개인맞춤화 신생물 백신을 위한 조성물 및 방법
JP6788500B2 (ja) 2013-10-23 2020-11-25 アメリカ合衆国 Ｍｕｃ１−ｃ癌タンパク質のｈｌａ−ａ２４アゴニストエピトープ及び組成物及び使用方法
WO2015077717A1 (fr) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions et méthodes pour diagnostiquer, évaluer et traiter un cancer au moyen d'un état de méthylation d'adn
WO2015085147A1 (fr) 2013-12-05 2015-06-11 The Broad Institute Inc. Typage de gènes polymorphes et détection de changements somatiques à l'aide de données de séquençage
EP2886127A1 (fr) * 2013-12-18 2015-06-24 Vaxon Biotech Procédé d'émulsification d'un peptide triepitope avec montanide et kits permettant de mettre en oeuvre celui-ci
JP7060324B2 (ja) 2013-12-20 2022-04-26 ザ・ブロード・インスティテュート・インコーポレイテッド ネオ抗原ワクチンによる併用療法
EP2977059A1 (fr) * 2014-07-22 2016-01-27 Vaxon Biotech Polypeptide immunogène composé de peptides cryptiques optimisés dérivés d'antigènes tumoraux restreints hla-b7 et leurs utilisations
WO2016100975A1 (fr) 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Biomarqueurs moléculaires pour l'immunothérapie d'un cancer
EP3234130B1 (fr) 2014-12-19 2020-11-25 The Broad Institute, Inc. Procédé pour profiler le répertoire de récepteurs de cellulles t.
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
EP3574116A1 (fr) 2017-01-24 2019-12-04 The Broad Institute, Inc. Compositions et procédés de détection d'un variant mutant d'un polynucléotide
MX2021010537A (es) * 2019-03-04 2021-12-10 Univ Health Network Receptores de linfocitos t y metodos de uso de estos.
CN111363026B (zh) * 2020-03-31 2022-03-25 浙江省中医院、浙江中医药大学附属第一医院（浙江省东方医院） 一种增强抗原多肽亲和力和稳定性的方法
WO2024138753A1 (fr) * 2022-12-30 2024-07-04 深圳吉诺因生物科技有限公司 Procédé de remplacement de site antigénique restrictif hla-a*24:02, polypeptide obtenu et son utilisation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6337200B1 (en) 1998-03-31 2002-01-08 Geron Corporation Human telomerase catalytic subunit variants
EP1455816A4 (fr) * 2000-10-19 2007-03-28 Epimmune Inc Peptides de liaison hla de classe i et ii et leurs utilisations
JP4624377B2 (ja) * 2001-12-10 2011-02-02 株式会社グリーンペプタイド 腫瘍抗原
EP1462456A4 (fr) * 2001-12-10 2005-09-21 Greenpeptide Co Ltd Antigenes tumoraux
WO2003087126A2 (fr) * 2002-04-05 2003-10-23 Epimmune Inc. Analogues heteroclitiques et procedes associes
CN101434647A (zh) 2004-01-20 2009-05-20 爱知县 由HLA-A2402-限制的Ep-CAM-特异的CTL识别的表位/肽及其应用
WO2007094924A2 (fr) 2006-01-19 2007-08-23 The Regents Of The University Of California Peptides de la transcriptase inverse de la télomérase humaine
WO2008010010A1 (fr) 2006-07-12 2008-01-24 Vaxon Biotech Identification, optimisation et utilisation d'épitopes cryptiques hla-b7 en immunothérapie

Also Published As

Publication number Publication date
US20120082692A1 (en) 2012-04-05
HUE030195T2 (en) 2017-04-28
ES2608715T3 (es) 2017-04-12
CN102387813A (zh) 2012-03-21
JP2012522500A (ja) 2012-09-27
US8900600B2 (en) 2014-12-02
DK2413956T3 (en) 2017-01-09
HRP20161710T1 (hr) 2017-02-24
CN102387813B (zh) 2018-07-31
JP5756792B2 (ja) 2015-07-29
BRPI0924827A2 (pt) 2019-01-08
WO2010112962A1 (fr) 2010-10-07
PT2413956T (pt) 2016-12-30
EP2413956A1 (fr) 2012-02-08
EP2413956B1 (fr) 2016-09-14
CA2756238A1 (fr) 2010-10-07

Similar Documents

Publication Publication Date Title
PT2413956T (pt) Identificação, optimização e utilização de epitopos crípticos hla-a24 para imunoterapia
EP2429585A4 (fr) Immunothérapie par vaccin
IL240898A0 (en) Antibodies against a5c and methods of using the antibodies
EP2593098A4 (fr) Procédés et compositions pour l'immunothérapie du cancer
EP2644151A4 (fr) Implant, corps d'implant, et corps de butée
IL221417A0 (en) Abrasive articles, method for their preparation and method of their use
EP2762488A4 (fr) Peptide pour la synthèse de la silice, et son utilisation
GB0905570D0 (en) Combined vaccines
EP2612911A4 (fr) Composition pour induire une cellule souche pluripotente, et utilisation de cette composition
EP2561072A4 (fr) Nanozymes, procédés de production de nanozymes, et procédés d'utilisation de nanozymes
EP2550269A4 (fr) Procédé et intermédiaires pour la préparation du lapatinib
PL2444103T3 (pl) Szczepionka przeciwko rakowi szyjki macicy
HK1169424A1 (en) Identification, optimization and use of shared hla-b0702 epitopes for immunotherapy hla-b0702
PT2391589E (pt) Clínquer sulfo-aluminoso e processo para a sua preparação
EP2408473A4 (fr) Procédés de vaccination
EP2573072A4 (fr) Composé d'indénoquinolone, son procédé de préparation et son utilisation
EP2486890A4 (fr) Butée pour implant
EP2575888A4 (fr) Immunisation par voie nasale
EP2881385A4 (fr) Nouveau composé azo, son utilisation et son procédé de préparation
HK1202070A1 (en) Vaccine for tumor immunotherapy
IL216102A0 (en) Combined measles-malaria vaccine
ZA201302213B (en) Centering aid for implantable sling
EP2701504A4 (fr) Dérivés du sulindac, leur utilisation et leur préparation
AP2013006816A0 (en) Ptocess for preparing pan-CDK inhibitors of the formula (I), and intermediates in the preparation
AP3680A (en) Glans retainer